RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) granted an inducement stock option covering 146,000 shares to a newly hired non-executive employee, the company said following a November 24 action by its board’s Compensation Committee.
The option was issued under Mineralys’ 2025 Employment Inducement Incentive Award Plan and structured to comply with Nasdaq Listing Rule 5635(c)(4), which permits equity awards granted as a material inducement to new employees. The option vests over four years, with 25% vesting on the first anniversary of the November 24 vesting commencement date and the remainder vesting monthly thereafter, contingent on continued service.
Mineralys is a clinical-stage biopharmaceutical company developing therapies for hypertension and related conditions, including chronic kidney disease and obstructive sleep apnea. Its lead drug candidate, lorundrostat, is an orally administered, selective aldosterone synthase inhibitor designed to address diseases driven by dysregulated aldosterone.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.